Thursday, June 30, 2022


Gandeeva Therapeutics announces search for new Chief Strategy Development Officer

Latest Posts

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

Ingenza Awarded Government Funding

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines & Diagnostics for Chronic Metabolic Disease

MultiOmic Health advises the partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD notes the test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly.

Pender & Howe, a North American executive search firm, is proud to lead the search for a Chief Strategy Development Officer on behalf of Gandeeva Therapeutics.

Directly supporting Gandeeva’s CEO, the Chief Strategy Development Officer (CSDO) will oversee the company’s strategic development objectives. Unlike a traditional Chief Scientific Officer, this unique opportunity will enable the CSDO to help define and execute the company’s scientific and corporate development strategy in collaboration with world-class scientists and industry leaders at Gandeeva.

Gandeeva Therapeutics is a rapidly growing biotechnology company that seeks to harness the power of cryo-EM technology and machine learning to design better drugs. The company’s platform overcomes limitations in using X-ray crystallography for drug design and avoids discovery dead ends that can arise from computational docking methods in the absence of experimental validation.

Gandeeva’s AI/ML-driven workflows enable high throughput structure determination combined with innovative biochemical methods to explore low-data targets, membrane proteins and protein complexes. From small molecules that induce protein proximity to engineered antibodies, Gandeeva’s approach breaks new ground to develop precision medicines for our most challenging diseases.

Gandeeva is headquartered in a 22,000 sq. ft. building in Greater Vancouver, British Columbia, set to be fully operational by December 2022.

Position details can be found here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine